Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00762710 · ClinicalTrials.gov registry record · Phase 2
Study of the Medication Prazosin for Alcohol Dependence
A Phase 2 study, sponsored by Seattle Institute for Biomedical and Clinical Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT00762710: Completed Phase 2 study, sponsored by Seattle Institute for Biomedical and Clinical Research.
NCT00762710 is a Phase 2 study that has completed, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 92 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00762710, a Phase 2 study, has completed, sponsored by Seattle Institute for Biomedical and Clinical Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the drug prazosin is effective for the treatment of alcohol dependency.
Primary Outcome
At the baseline and final medication visits, the Form 90 (19) was used to assess alcohol and drug use for the preceding 90-day period
Interventions
- DRUG Placebo medication
- DRUG Prazosin medication
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2008-01 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
What the finished NCT00762710 record still lists
NCT00762710 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo medication is the first listed.
NCT00762710 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00762710 about?
NCT00762710 is a clinical study titled "Study of the Medication Prazosin for Alcohol Dependence". The purpose of this study is to determine whether the drug prazosin is effective for the treatment of alcohol dependency.
What is the current status of trial NCT00762710?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2008-01. Estimated completion is 2014-06.
What interventions are being tested in trial NCT00762710?
The interventions under investigation include: Placebo medication (DRUG), Prazosin medication (DRUG).
Who is sponsoring clinical trial NCT00762710?
This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00762710's enrollment target sits among peer trials
92 767th of 2000 higher than 1,230 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia